Asser, Andres, Koks, Sulev 
ORCID: 0000-0001-6087-6643, Snellman, Anniina, Haaparanta-Solin, Merja, Arponen, Eveliina, Gronroos, Tove, Nairismagi, Jaak, Bergquist, Jonas, Soomets, Ursel, Piip, Piret et al (show 5 more authors)
(2016)
Increased striatal VMAT2 binding in mice after chronic administration of methcathinone and manganese.
BRAIN RESEARCH, 1652.
pp. 97-102.
![[img]](https://livrepository.liverpool.ac.uk/style/images/fileicons/text.png) |
Text
Manuscript_BRes_revised.pdf - Author Accepted Manuscript Download (881kB) |
Abstract
Intravenous use of a psychostimulant drug containing methcathinone (ephedrone) and manganese causes an irreversible extrapyramidal syndrome in drug abusers. We aimed to reproduce the syndrome in mice to evaluate dopaminergic damage. C57/B6 mice were intraperitoneally injected once a day with the study drug or saline for a period of 27 weeks. Motor activity was recorded in an automated motility-box. After 13 and 27 weeks of treatment, ex vivo digital autoradiography was performed using [<sup>11</sup>C]dihydrotetrabenazine ([<sup>11</sup>C]DTBZ). After 27 weeks of treatment [<sup>11</sup>C]DTBZ autoradiography demonstrated a significant increase in the striatum-to-cerebellum binding ratio compared with saline treated controls. At the same time point, there was no evident change in motor activity. Increased [<sup>11</sup>C]DTBZ binding may indicate vesicular monoamine transporter type 2 (VMAT2) function is altered. The lack of extrapyramidal symptoms in animals could be attributed to low dosing regimen or high metabolic rate.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Manganism, Ephedrone, Methcathinone, VMAT2, PET |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 02 Aug 2017 07:48 |
| Last Modified: | 19 Jan 2023 06:58 |
| DOI: | 10.1016/j.brainres.2016.09.034 |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3008766 |
Dimensions
Dimensions
